Glenmark Launches Biosimilar Antidiabetic Drug in India
By Rediff Money Desk, NEWDELHI Jan 03, 2024 10:51
Glenmark Pharmaceuticals launches Lirafit, a biosimilar antidiabetic drug, in India at a lower cost than Liraglutide, providing effective treatment for type 2 diabetes mellitus.
New Delhi, Jan 3 (PTI) Glenmark Pharmaceuticals on Wednesday said it has launched a biosimilar of the popular antidiabetic drug, Liraglutide in India.
The drug is being marketed under the brand name Lirafit following the approval from the Drug Controller General of India (DCGI), the company said in a statement.
It is priced at around Rs 100 for a standard dose of 1.2mg (per day) and will lower the cost of therapy by approximately 70 per cent, the company claimed.
Lirafit will be available only under prescription.
"Clinical trials have shown that it helps improve glycemic control in adult type 2 diabetes mellitus patients along with atherosclerotic cardiovascular diseases (ASCVD) and obesity," Glenmark Pharmaceuticals President and Business Head India Formulations, Alok Malik said.
Liraglutide has also proven to have a positive impact on cardiac and renal safety outcomes among patients in clinical trials, making it an effective choice of treatment for patients with type 2 diabetes mellitus, he added.
"With this launch, we have now ventured into the injectable antidiabetic market taking another significant stride in the diabetes therapy space," Malik said.
The drug is being marketed under the brand name Lirafit following the approval from the Drug Controller General of India (DCGI), the company said in a statement.
It is priced at around Rs 100 for a standard dose of 1.2mg (per day) and will lower the cost of therapy by approximately 70 per cent, the company claimed.
Lirafit will be available only under prescription.
"Clinical trials have shown that it helps improve glycemic control in adult type 2 diabetes mellitus patients along with atherosclerotic cardiovascular diseases (ASCVD) and obesity," Glenmark Pharmaceuticals President and Business Head India Formulations, Alok Malik said.
Liraglutide has also proven to have a positive impact on cardiac and renal safety outcomes among patients in clinical trials, making it an effective choice of treatment for patients with type 2 diabetes mellitus, he added.
"With this launch, we have now ventured into the injectable antidiabetic market taking another significant stride in the diabetes therapy space," Malik said.
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Thinkink Picturez
- 1.94 (+ 4.86)
- 69820171
- Rajnish Wellness
- 1.78 (+ 4.09)
- 54627483
- G G Engineering
- 1.80 (+ 1.12)
- 53423097
- GTL Infrastructure
- 2.32 ( 0.00)
- 34510899
- Vodafone Idea L
- 8.10 ( -0.25)
- 34418651
MORE NEWS
Brookfield India REIT Raises Rs 3,500 Cr via QIP
Brookfield India REIT launches a Qualified Institutional Placement (QIP) issue to raise...
Rajasthan Tourism Potential: Inclusive...
Union minister Gajendra Singh Shekhawat highlights Rajasthan's tourism potential,...
India Airlines: 809 Hoax Bomb Threats in 5 Years
Airlines in India faced 809 hoax bomb threats in the last five years, with a surge in...